Merck says experimental RSV treatment protected infants in trial
The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021. Andrew Kelly | Reuters Merck on Thursday said its experimental treatment …
GSK plc
Wegovy could face Medicare drug price negotiations next
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first …
$1 billion in cost cuts, 10 product launches planned
Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. Plexi Images | GHI | UCG | Universal Images Group | Getty Images Moderna on Thursday said it plans to cut around $1.1 billion …
Moderna (MRNA) earnings Q2 2024
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. …
Pfizer stock recovers after Covid decline but some employees struggle
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide …
FDA approves Merck pneumococcal disease vaccine designed for adults
Zoom In IconArrows pointing outwards Merck’s new pneumococcal vaccine. Courtesy: Merck The Food and Drug Administration on Monday approved Merck‘s new vaccine designed to protect adults from a bacteria known …
FDA approves GSK RSV vaccine for adults 50 to 59
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus …
GSK plunges after U.S. court makes Zantac ruling
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Matthew Childs | Reuters LONDON — Shares of British pharmaceuticals giant GSK plunged 9% …
FDA approves Moderna RSV vaccine for seniors
Nikos Pekiaridis | Lightrocket | Getty Images The Food and Drug Administration on Friday approved Moderna’s vaccine for respiratory syncytial virus for adults ages 60 and above, the company’s second-ever …
Moderna says RSV vaccine FDA approval delayed to end of May
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end …